Nurix Therapeutics, Inc. NRIX
23.08
(0.57)
(2.41%)
as of 25 Sep
- Market cap
- $2.5B
- P/E
- 0.0×
Follow NRIX
| May '26 | Feb '26 | Nov '25 | Aug '25 | Older periods | |
|---|---|---|---|---|---|
| (80.30%) | (61.40%) | (49.63%) | (65.35%) |
+8 more TTM periods Free account |
|
| (60.57%) | (47.20%) | (38.96%) | (47.25%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(84.40%) | (61.02%) | (48.72%) | (64.63%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(2.74) | (2.47) | (3.04) | (2.87) | |
Free Cash Flow |
(304.53) | (271.85) | (263.47) | (241.36) | |
Capital Expenditures |
(10.82) | (11.56) | (14.00) | (10.98) | |
Piotroski F-Score |
1.00 | 1.00 | 3.00 | 3.00 | |
| Other line items | |||||
Cash ROIC |
(34.71%) | (25.48%) | (22.04%) | (28.76%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
927.31% | 461.66% | 377.36% | 359.80% | |
Selling, General and Administrative Expense of Revenue |
155.06% | 77.60% | 62.80% | 59.52% | |
Share Based Compensation of Revenue |
107.84% | 53.84% | 45.21% | 44.67% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.86 | 0.88 | 0.94 | 0.94 | |
Depreciation/Fixed assets |
0.35 | 0.38 | 0.38 | 0.35 | |
Capex/Depreciation |
(1.56) | (1.41) | (1.64) | (1.52) | |
Revenue per Share |
0.33 | 0.65 | 0.97 | 0.99 | |
Operating CF per Share |
(2.64) | (2.36) | (2.88) | (2.74) | |
Capex per Share |
(0.10) | (0.10) | (0.16) | (0.13) | |
Capex to Sales |
0.29 | 0.16 | 0.17 | 0.13 | |
Net Profit Margin |
(928.44%) | (411.37%) | (314.90%) | (292.50%) |
Columns are period end dates